Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality—A retrospective.

Slides:

Advertisements

Similar presentations

Perimenopausal migraine in women with vasomotor symptoms E. Anne MacGregor Maturitas Volume 71, Issue 1, Pages (January 2012) DOI: /j.maturitas

Advertisements

Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /

Clinical leadership development in a pre-registration nursing curriculum: What the profession has to say about it Angela Brown, Patrick Crookes, Jan Dewing.

Date of download: 9/19/2016 From: Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use: A Nationwide.

Volume 376, Issue 9753, Pages (November 2010)

Coronary calcium score, albuminuria and inflammatory markers in type 2 diabetic patients: Associations and prognostic implications Akın Dayan, Burcu.

Engineered antibodies: A new tool for use in diabetes research

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Volume 352, Issue 9131, Pages (September 1998)

Persistence with statin therapy in diabetic and non-diabetic persons: a nation-wide register study in in Finland Arja Helin-Salmivaara, Piia.

Volume 136, Issue 4, Pages (October 2015)

Temporal trends in survival after out-of-hospital cardiac arrest in patients with and without underlying chronic obstructive pulmonary disease Sidsel.

Organization of wound healing services: The impact on lowering the diabetes foot amputation rate in a ten-year review and the importance of early debridement

Hand grip strength in patients with type 2 diabetes mellitus

Helicobacter pylori infection associated with type 2 diabetic nephropathy in patients with dyspeptic symptoms Fei Zhou, Xiaoqin Zhong, Jingbo Chen, Chunguo.

Gender differences in the association of insulin resistance with metabolic risk factors among Korean adolescents: Korea National Health and Nutrition.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment Ippei Kanazawa, Ken-ichiro Tanaka, Masakazu.

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis Zhaowei Zhu, Zhoujun Shen, Yingli Lu, Shan Zhong,

Utility of HbA1c for diagnosis of gestational diabetes mellitus

Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes by Gunnar H. Gislason, Jeppe N. Rasmussen, Steen.

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal Gregory.

All-Cause and Cause-Specific Mortality in Patients with Psoriasis in Taiwan: A Nationwide Population-Based Study Meng-Sui Lee, Yi-Chun Yeh, Yun-Ting.

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both Nadia Aissaoui, Edith Martins,

Performance of the RapidHIT™200

Management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery: association with adverse events A. Rodriguez, N. Guilera,

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Frequency of cancer in patients operated on for acute peripheral arterial thrombosis and the impact on prognosis Chalotte Winther Nicolajsen, MD, Maja.

Metformin Joins Forces with Microbes

Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without.

Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G

Perioperative statin therapy in patients at high risk for cardiovascular morbidity undergoing surgery: a review B.A. de Waal, M.P. Buise, A.A.J. van.

Risk of Multiple Sclerosis in Patients with Psoriasis: A Danish Nationwide Cohort Study Alexander Egeberg, Lotus Mallbris, Gunnar Hilmar Gislason, Lone.

Volume 375, Issue 9725, Pages (May 2010)

Volume 376, Issue 9753, Pages (November 2010)

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Volume 371, Issue 9627, Pages (May 2008)

Volume 378, Issue 9786, Pages (July 2011)

Volume 382, Issue 9894, Pages (August 2013)

Volume 375, Issue 9719, Pages (March 2010)

Cardiac risk in patients undergoing carotid endarterectomy: Impact on perioperative and long-term mortality William C. Mackey, MD, Thomas F. O'Donnell,

Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease Tetsuro Tsujimoto, Hiroshi Kajio

ACST: which subgroups will benefit most from carotid endarterectomy?

David Montero, Agnès Vinet, Christian K. Roberts

Clinical Outcomes After Treatment of Cocaine-Induced Chest Pain with Beta-Blockers: A Systematic Review and Meta-Analysis Kevin Bryan Lo, MD, Hafeez.

Antidepressant use and risk for mortality in 121,252 heart failure patients with or without a diagnosis of clinical depression Corline Brouwers, Stefan.

Age-dependent care and long-term (20year) mortality of 14,434 myocardial infarction patients: Changes from 1985 to 2008 Sjoerd T. Nauta, Jaap W. Deckers,

Volume 373, Issue 9672, Pages (April 2009)

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Role of Niacin in Current Clinical Practice: A Systematic Review

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

Weekend versus weekday mortality in ST-segment elevation acute myocardial infarction patients between 1985 and 2008 Sanne M. Snelder, Sjoerd T. Nauta,

Β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease – A Danish Nationwide Study of 1·3 Million Individuals Anne Orholm Nielsen, Lars.

Volume 80, Issue 6, Pages (September 2011)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus James H. O'Keefe, MD, Mohammad Abuannadi,

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Volume 75, Issue 1, Pages (January 2009)

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Effect of consent rituals on mortality in emergency care research

Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative.

Magnus Dalén, MD, Torbjörn Ivert, MD, PhD, Martin J

Presentation transcript:

Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality—A retrospective nationwide study Ulrik Madvig Mogensen, Charlotte Andersson, Emil Loldrup Fosbøl, Tina Ken Schramm, Allan Vaag, Nikolai Madrid Scheller, Christian Torp-Pedersen, Gunnar Gislason, Lars Køber Diabetes Research and Clinical Practice Volume 107, Issue 1, Pages 104-112 (January 2015) DOI: 10.1016/j.diabres.2014.09.047 Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

Fig. 1 Flowchart. MI=myocardial infarction. Diabetes Research and Clinical Practice 2015 107, 104-112DOI: (10.1016/j.diabres.2014.09.047) Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

Fig. 2 Proportions of initial drug use (insulin secretagogoues (IS), metformin or a combination of IS and metformin at initiation of glucose lowering therapy) among included patients. There was no interaction between initial drug use and the used combination treatment (p=0.71). Diabetes Research and Clinical Practice 2015 107, 104-112DOI: (10.1016/j.diabres.2014.09.047) Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

Fig. 3 Rate Ratios (RR) and 95% confidence intervals (95% CI) for mortality (a), cardiovascular mortality (b) and a combined endpoint of cardiovascular death, myocardial infarction or stroke (c) when comparing individual insulin secretagogoues+metformin using glimepiride+metformin as reference. Diabetes Research and Clinical Practice 2015 107, 104-112DOI: (10.1016/j.diabres.2014.09.047) Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions